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Multi attribute utility instruments (MAUI) are being increasingly used to generate utility data which can be used 
to calculate quality adjusted life years (QALYs). This QALY data can then be incorporated into a cost utility 
analysis as part of an economic evaluation, to inform health care resource allocation decisions. Many health care 
decision making bodies around the world such as The National Institute for Health and Care Excellence require 
the use of generic MAUIs. Recently there has been a call for greater input of patients in the development of 
patient reported outcome measures and this is now actively encouraged. By incorporating the views of patients, 
greater validity of an instrument is expected and it is more likely that patients will be able to self-complete an 
instrument, which is the ideal when obtaining information about a SDWLHQW¶V health related quality of life. This 
paper examines the stages of MAUI development and the scope for patient and/or public involvement at each 
stage. The paper then reviews how much the main generic MAUIs have incorporated the views of patients/the 
public into the development of their descriptive systems at each of these stages and the implications of this. The 
review finds that the majority of MAUIs had very little input from patients/the public. Instead, existing literature 
and/or the views of experts was used. If we wish to incorporate patient/public views in future development of 
MAUIs, then qualitative methods are recommended.  
 
 
Key Points for Decision Makers 
x The majority of multi attribute utility instruments had very little involvement of patients in the 
development of their descriptive systems 
x The descriptive systems of multi attribute utility instruments were mostly developed using top down 
methods, which made use of existing literature and/or views of experts in determining what should be 
included 
x If patient or public views are to be incorporated in the development of descriptive systems in the future, 
qualitative methods are recommended.  
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1. Introduction 
Health care decision making is increasingly using economic evaluation to help inform the allocation of health 
care resources. This has been formalised in many countries through the establishment of decision making bodies 
who require submission of evidence on the cost effectiveness of interventions as part of their requirements when 
deciding whether to recommend interventions. These decision making bodies often have sets of guidelines 
which give guidance on the methods to use to provide this evidence. Typically the preferred form of economic 
analysis is cost utility analysis (CUA) with the outcomes measured in quality adjusted life years (QALYs). This 
gives the advantage to the decision maker of being able to compare interventions both within and across clinical 
areas, as the QALY is a common metric for measuring health outcomes [1]. QALYs are composed of two 
components; the number of life years and a quality adjustment weighting, ranging on a scale from 0 (equivalent 
to being dead) to 1 (full health). These two components are combined to calculate the number of QALYs. For 
example, 8 years of life with a quality weighting of 0.6 would equal 4.8 (8*0.6) QALYs. To obtain the quality 
adjustment weight, a common approach is to make use of off the shelf preference based measures (PBMs), 
sometimes called multi attribute utility instruments (MAUIs).  
A MAUI is a measure of health related quality of life that consists of two components, a descriptive system and 
a set of preference weights for all the possible health states defined by this descriptive system. The descriptive 
system is typically constructed from a number of domains of health related quality of life, each with a number of 
response options (levels). A patient will be asked to complete the instrument by answering a series of questions 
about what level they are at for each of the domains. The answers to these questions categorize the patient into 
what is termed a heath state. Each MAUI has a different number of possible health states that can be defined by 
its descriptive system. For example, the EQ5D 3L [2] consists of 5 dimensions (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression), each with 3 levels and therefore has 243 possible health states, 
whereas the Health Utilities Index 3 (HUI3) has 8 dimensions each with 5 or 6 levels, giving a possible 972,000 
health states [3]. For each MAUI, there is a pre-existing set of preference weights which give a utility value to 
each of the health states defined by the MAUIs descriptive system. These preference weights have been 
developed by valuing a subset of the total health states in a descriptive system and then modelling to predict a 
value for every health state. Typically, the health states have been valued using a choice based technique, such 
as the standard gamble (SG) or time trade off (TTO) and with members of the adult general population. [4]   
A generic MAUI is one that is intended to be applicable to all clinical areas and the domains are not specific to 
any particular health condition. In contrast to this, a condition specific MAUI is specific to a clinical area or 
condition, for example asthma or diabetes. Conditions specific (CS)MAUIs  are often called for when generic 
measures are considered to be insensitive to the health condition being considered [5]. 
Until recently, research into MAUIs had typically focussed on the valuation side (generating the preference 
weights) rather than the measurement side (the descriptive system used) [5], in particular with the generic 
measures. As CS MAUIs have generally been developed more recently, when developing their descriptive 
systems they are able to use methods that have been evolving, such as the use of qualitative techniques to inform 
item development and Rasch analysis to inform item selection and refinement of the descriptive system [6]. 
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MAUIs take into account SHRSOH¶Vpreferences for the different domains within a measure. Typically in the 
generic measures, these preferences are taken from the general population (as recommended by agencies such as 
the National Institute for Health and Care Excellence [7]. As tax payers representing society and potential users 
of the healthcare system, this is often felt to be the most appropriate population [8]. However, in terms of what 
should be valued, it may not be the case that patients and/or the general public have been as involved in 
determining what should be included and what is important to measure and therefore their views for what should 
be in a descriptive system have not been incorporated. 
 
2. The importance of incorporating patient views  
When a MAUI is used, the ideal situation is that patients self complete the descriptive system which defines 
them into a particular health state. The pre existing preference weights are then applied. By patients self 
completing the descriptive system, we ensure that the information about their health related quality of life at any 
point in time comes directly from them. It is known that when instruments are completed by proxy, bias can be 
introduced and so where possible, it is best practice to obtain the information directly from the patient [9]. 
Given this, it is important that the instruments are amenable to completion directly by the patient and are reliable 
and valid measures.  
Involving patients/users in the development of a descriptive system helps to increase the validity of an 
instrument. In particular, the content validity and relevance of an instrument, whereby the items and response 
options included are relevant to the population and the language and terminology used to describe them is 
appropriate [9]. It will also improve the responsiveness to change of a measure as it will ensure only outcomes 
of relevance to the patient are included [9]. 
The U.S Food and Drug Administration (FDA) require that instruments show evidence that their items have 
been generated through taking account of the experience and perspective of the patient group [10]. In more 
recent years, the importance of involving patients and/or lay people in the development of quality of life 
measures has been more widely recognised [11]. 
 
 
3. Methods of descriptive system development 
There are three key stages to developing an MAUI: firstly, creation of the descriptive system; secondly, 
valuation of a subset of the health states and thirdly, modelling to produce a value for every health state [16]. In 
this paper, the focus is on the development of the descriptive system.  
The development of an MAUI has to work to additional constraints compared to a non utility based instrument 
as it has to be amenable to valuation of the health states. To be amenable, descriptive systems should ideally 
contain a limited (no more than 7±2) domains and also ideally have a series of response options which are 
ordinal and range in levels of increasing (or decreasing) severity/frequency [5]. 
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Within these constraints, the development of a descriptive system can be broken down into a number of stages: 
1. Generation of items/domains for potential inclusion 
2. Selection and/or refinement of items  
3. Testing of the descriptive system  
Each of these stages has the potential for patient or public involvement and these are now considered in turn. 
3.1 Generation of items/domains for potential inclusion 
Two contrasting methods of item/domain development have been reported by Stevens and Palfreymen [12]. 
They are a bottom up methodology and a top down methodology. A bottom up methodology involves working 
with patients and/or members of the public, and seeks their views on how their life is affected by their particular 
health problem or condition. This approach typically requires the use of qualitative methods to generate items, 
for example through focus groups or individual interviews [9]. Stevens and Palfreyman give two examples of 
non MAUIs that have taken this approach: the DEMQol, where both patients and carers were interviewed to 
identify items [13] and the Nottingham Health Profile, which used patients and the general public [14]. In 
contrast, a top down methodology generally takes information from existing sources, such as the literature, other 
instruments and health surveys and uses these to generate a pool of items for potential inclusion in the 
instrument. Clearly there is greater scope for patients/the public to be involved through the use of a bottom up 
methodology. 
3.2 Selection and/or refinement of items 
This stage involves selecting out the items that are going to be included in the measure. There are a number of 
ways of doing this. It could be done through the use of qualitative methods whereby either patients/the public or 
perhaps clinical/other experts are asked what they think and are asked to select items. Other methods include 
using psychometric testing whereby the validity and reliability are tested and items selected/refined on the basis 
of these. For example, it may be found that some items are measuring the same thing are thereby one can be 
removed. Rasch analysis and factor analysis are also methods that can be used [15].  Factor analysis is useful for 
establishing instrument dimensions and Rasch analysis for selecting items for including and/or reducing the 
number of item levels [15]. The majority of these methods offer scope for the inclusion of patient/RUWKHSXEOLF¶V
views.  
3.3 Testing of the descriptive system 
 
Final testing of a descriptive system is useful as it can highlight any issues/problems with completion and also 
offers further scope for refinement before the final descriptive system is decided on. An instrument could be 
tested on a patient or general population group and the practicality, validity and reliability measured. This stage 
again offers scope for patients or the general population to be involved. 
 
 
4. Review of the main generic MAUIs 
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This paper reviews to what extent existing generic adult MAUIs intended for use in calculating QALYs took 
account of patient and/or public input in the development of their descriptive systems and considers the 
implications of this. 
The generic MAUIs have all been developed using different methods. This paper reviews the amount of 
patient/public input for each MAUI for the three key stages of descriptive system development outlined 
previously. For each MAUI, the key literature describing its development was identified by searching the 
literature, reviewing MAUI websites and contacting developers where necessary.  There are currently six 
generic MAUIs that enable the calculation of QALYs [16]: The EuroQoL 5D (EQ5D); the Short Form 6D 
(SF6D); The Health Utilities Index Mark 2 and Mark 3 (HUI2/3); the 15D; the Australian Quality of Life 
(AQoL) and the Quality of Well Being (QWB). Richardson et al (REF 2011 paper 64) recently reviewed the use 
of them in the literature. They found that the EQ5D was by far the most commonly used (63.2% of studies). Use 
of the HUI3 was 9.8%, the SF6D 8.8%, the 15D 6.9%, the HUI2 4.6%, AQoL 4.3% and the QWB 2.4%. All 
these six measures are included in the review. The EQ-5D and AQoL both have versions for 
children/adolescents (EQ-5D Youth (EQ-5D-Y) [2] and AQoL 6D respectively [17]). In addition, the Child 
Health Utility 9D (CHU9D) has recently been developed as a new paediatric MAUI [18]. These child 
instruments are also included in the review.  
Table 1 below shows a summary of the included generic MAUIs, including the number of dimensions, levels 
and whether there was patient and/or public involvement at each of the three key stages. The country of origin 
and year preference weights for each instrument became available is also shown, although instruments typically 
take a number of years to develop. Each of these MAUIs is then considered in turn. 
 
Table 1: Summary of whether there was patient/public involvement at each stage. 
 
 
  
  Patient/public involvement 
MAUI Country of 
Origin 
Year* Number of 
dimensions 
Number of 
levels 
Item/domain 
generation 
Refinement Testing 
EuroQoL-
5D-3L 
Europe/UK 1995 5 3 no Yes no 
EuroQoL-
5D-5L 
Europe/UK 2012** 5 5 no yes yes 
EuroQoL-
5D-Y 
Europe/UK Preference 
weights not 
yet 
available 
5 3 no yes yes 
Short 
Form-6D 
UK/USA 2002 6 4-6 no no no 
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Health 
Utilities 
Index 2 
Canada 1996 6 4-5 no yes no 
Health 
Utilities 
Index 3 
Canada 2002 8 5-6 no no No 
15D Finland 1989 15 4-5 no yes yes 
Australian 
Quality of 
Life-8D 
Australia 2009 8 4 no no no 
Australian 
Quality of 
Life-6D 
Australia 2004 6 4-6 no no yes 
Quality of 
Well Being 
USA 1976 3 plus 27 
symptoms/p
roblems 
2-3 no no no 
Child 
Health 
Utility 9D 
UK 2012 9 5 yes yes yes 
*Year preference weights available  
**Interim scoring available 
 
EQ-5D-3L 
The EQ-5D-3L was developed by a group of researchers across 5 countries [2]. The researchers used their own 
expertise, together with a review of other generic HRQoL measures available at the time to generate a core set 
of domains which they felt reflected the most important concerns of patients themselves [19].  The resulting 
descriptive system consisted of 6 dimensions each with 2 or 3 levels. There were some experiments with this 
and the result was that a number of changes were made and it became a 5 dimensional classification system with 
3 levels each [19]. A large national survey of lay concepts of health was carried out by Van Dalen [20] and 
following this, there was work by Gudex [21] to determine whether an additional dimension of energy should be 
added but it was found that it was not necessary [22]. 
  
As the initial pool of items for consideration was generated from existing literature, there was no involvement of 
patients or the public in the first stage, however there was some involvement of patients/the public in the 
subsequent refinement of the instrument from the input into the survey of lay concepts of health. 
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EQ-5D-5L 
The EQ-5D-3L has existed for a number of years and has been widely used and validated. However, there is 
evidence that it is not always sensitive enough with just 3 levels. In response to this, a 5 level version was 
created by a Euroqol Group Task Force, with the aim of increasing sensitivity and reducing ceiling effects. This 
was undertaken simultaneously in England and Spain. After discussion by the task force, the dimensions were 
kept the same but it was decided to increase the number of levels to 5 (based on evidence from psychometric 
literature and other sources). Potential labels for the new 5 levels were generated from a review of existing 
health-related quality-of-life instruments, a review of the literature on response scaling, hand searching of 
dictionaries and thesauruses, and informal interviews with lay respondents to find out how they described 
different severities of health problems [23]. The existing structure of the EQ-5D-3L was kept and the new labels 
had to fit within this. Pilot work was undertaken to reduce the pool down to a manageable level of 10-12 labels 
per dimensions for consideration. A response scale exercise was done with lay respondents in order to select 
labels from the pool. Respondents were also asked for their input on whether the new labels suited the 
dimensions (or not). This exercise produced 2 versions which went forward for further testing in 8 focus group 
(4 consisting of healthy people and 4 consisting of people with a chronic illness). This testing aimed to assess 
the ease of use, comprehension, interpretation, and acceptability of the 2 versions and decide which was to be 
the final one [23]. The result was the new 5 dimension, 5 level version. Testing has since been carried out to 
compare it with the EQ-5D-3L in various clinical populations but not with the purpose of refining the 
descriptive system. 
 
As with the EQ-5D-3L, there was mainly patient/public input in the second stage of the descriptive system 
development. The dimensions were kept the same as the original 3 level version and a pool of potential labels 
for the new levels was generated from existing literature. Patients and the public were used extensively in the 
selection of the levels, both in the response scaling task and then in the subsequent focus groups, which included 
both well people and chronically ill people.  
 
EQ-5D-Y 
In 2006, a child friendly version of the EQ-5D was developed and named the EQ-5D Youth (EQ-5D-Y). 
The descriptive system has the same 5 dimensions as the EQ-5D-3L, but uses a child friendly wording 
(mobility, looking after myself, doing usual activities, having pain or discomfort, feeling worried, sad or 
unhappy). There are 3 levels for each dimension (no problems, some problems, a lot of problems) [24]. It is 
recommend for children age 8-15 years old, although the developers note that for children age 12-15 years , it is 
also possible to use the adult EQ5D and for children age 4-7 years old there is a proxy version. The EQ-5D-Y 
was developed collaboratively by teams from 7 countries, who formed a task force on behalf of the Euroqol 
group. A decision was made to keep the existing concepts for the dimensions the same as the adult version. The 
task force considered evidence from studies where the EQ-5D-3L had been used in younger populations and 
results from previous qualitative assessments and used this to alter the instructions, dimension descriptions and 
wording of response levels where they felt it was necessary [25]. The resulting descriptive system was then 
translated into several languages and qualitative assessment undertaken with children. Some versions were 
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subsequently altered to take into account cultural differences, but no changes were felt to be necessary for the 
English language version. Subsequently, psychometric testing was undertaken with children in a range of 
European countries and South Africa [26]. These results were not used to refine the descriptive system. 
 
Patients/the public were not involved in the initial development stage as the dimensions and levels for 
consideration were to be kept the same as the existing adult instrument. Children were involved in the 
refinement stage, as the task force took account of previous qualitative assessments with children as to the 
language used in the descriptive system. The results of this were used (along with consideration of studies where 
the EQ-5D-3L had been used in younger people) to help determine what wording should be used in the final 
version in order that children would be able to understand the original concepts [25]. Children were involved in 
thefinal stage, which was testing the instrument with the population. Children were also involved in the 
refinement of some of the translated versions, in order to make sure the instrument was culturally valid.  
 
EQ-5D Bolt ons 
There has also been recent work looking at the use of bolt ons for the EQ-5D. Bolts ons are dimensions that are 
added to an instrument to overcome inadequacies in a particular population [27]. Three bolt ons were developed: 
hearing; vision and tiredness. The wording and development of these bolt ons all came from the literature and 
decisions made by the research team. There was no patient or public involvement.  
 
SF-6D 
The SF-6D was developed by a team at The University of Sheffield. It takes its content from the Short Form-36, 
which is a widely used health status measure around the world [28]. The SF-36 takes its content from existing 
surveys used in health research and subsequent refinement in a series of medical outcome studies. It assesses 
patients on 8 dimensions on health related quality of life [29].  The team revised the SF-36 into a 6 dimensional 
health state classification system in order to make it amenable to valuation [30]. The team made use of extensive 
factor analysis that had been carried out by Ware et al [31] already in informing their selection of dimensions.  
 
Patients or the public were not involved in the first stage of generating potential items to include as this research 
took an existing instrument which was already developed. The public were not involved in the second stage as 
use was made by the team of the results of studies involving factor analysis where the SF-36 had been 
administered to patients. There was no third stage of testing prior to valuation in this study.  
 
HUI2/HUI3 
The HUI2 consists of 6 dimensions (sensation, mobility, emotion, cognition, self-care and pain), each with 
between 4 and 5 levels andwas designed for use with children. The instrument was originally developed for use 
in childhood cancer but has subsequently been used as a generic measure [32]. The HUI2 was developed from a 
review of epidemiological surveys and a review of the literature which generated a large pool of potential 
attributes. A sample of 84 child and parent pairs of the same gender living in the same household then rated 
these items, to select attributes for inclusion.  The populations were sampled from schools in Hamilton, Ontario, 
Canada and the child was in grade 7 or 8 at school (age 12/13 years) [33]. 
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The HUI2 did not involve patients or the public in the first stage as the generation of potential items came from 
a review of existing literature. The public were involved in the second stage of selecting items, through the 
rating work done as child and parent pairs. Whilst children were involved in the rating stage along with their 
parents, the investigators made an expert judgement as to what attributes were relevant to the purpose for which 
the instrument was being developed when forming the initial list of attributes [34]  
 
The Health Utilities Index 3 (HUI3) was developed from the HUI2 by increasing the number of dimensions to 8 
(through the separating out of some dimensions and the removal of others) and increasing the number of levels 
for all dimensions to between 5 and 6 [3]. It was designed for use by adults. The development was carried out by 
the research team who developed the HUI2 and the decisions concerning what dimensions to include were based 
on experience and evidence from using the HUI2. The aim of the HUI3 was to have full structural independence 
[3]. 
 
15D 
The 15D was based on a review of the Finnish health policy documents [16]. It originally had 12 dimensions 
and then was revised to 15 following feedback from users and health professionals [35]. Two large patient 
surveys were then carried out in which respondents were asked to identify dimensions that should be omitted or 
added. These findings, combined with factor analysis resulted in the final version [36, 37].  
There was no involvement of patients/the public in the first stage however as part of the process of refinement, 
patients were involved by giving feedback as users and also later, in determining whether dimensions should be 
added or omitted.  
 
AQoL-8D 
The Assessment of Quality of Life descriptive system was developed from a literature review of existing 
instruments, focus groups with clinicians and construction surveys [16]. These construction surveys 
administered large numbers of items to selected patients and the public. Factor analysis and structural equation 
modelling was then used to select items for inclusion. A survey to determine values for a selection of health 
states was also undertaken with 629 respondents (half patients, half general population). The results of this were 
used to refine the descriptive system and the AQoL-8D was produced.  
 
Patients/the public were not directly involved in any of the stages of development.  The results of the surveys 
conducted with patients and the public were used to inform the selection of items for inclusion but this was not 
direct involvement.   
 
AQoL-6D 
The AQoL-6D was derived from the existing AQoL-8D adult version. It was designed to increase sensitivity to 
health state variations close to normal health and to extend the coverage of AQoL. A subsequent study refined it 
for application in adolescents by interviewing adolescents and testing the semantics and language [17]. It has six 
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dimensions, (independent living, social relationships, physical senses, psychological wellbeing, pain and 
coping) [17]. Patients/the public were not involved in the first or second stages, as this was derived from an 
existing measure. They were involved in the third stage to some extent as the semantics and language was tested 
with them.  
 
 
QWB 
The Quality of Well Being (QWB) consists of 3 multi response items and 27 symptom/problem groups, giving a 
total of 945 states. 
It draws its items mainly from an existing US Health Interview Survey, a Social Security Administration Survey 
and several rehabilitation scales and ongoing community surveys [38]. 
Patients/the public were not involved at any of the 3 stages as items were taken from existing survey instruments 
and selected by researchers.  
CHU9D 
The CHU9D was developed by Stevens [39-41]. It was developed from the start to be a generic paediatric health 
related quality of life measure for use in economic evaluation. Dimensions were developed through 74 one to 
one interviews with children recruited through schools, who were asked to describe any health problems they 
had and how these problems impacted on their lives. Children with a wide range of acute and chronic health 
problems were included in the interviews until saturation was reached. The qualitative interview data was also 
used to develop potential response level wordings for inclusion. Ranking work with 31 children was then 
undertaken to determine the ordinality of the response level wordings and also to remove any redundant 
wordings. A draft descriptive system was then produced which was then tested on both a general population 
(through schools, n=150) and a clinical population including medical, surgical and day case patients (recruited 
through a hospital, n=98). The results of this testing then informed the subsequent refinement of the draft 
instruments to produce the final version for valuation.  
The general paediatric population and patients were involved in all 3 stages of development here, in stage 1, 
item generation (qualitative interviews), in stage 2, selection of items for inclusion and in stage 3, testing and 
refinement of the instrument. 
 
 
5. Discussion  
The majority of the generic MAUIs have used a top down approach in the development of their descriptive 
systems, that is, the content has been derived from existing literature, instruments and health surveys. 
Patient/public involvement, if any, was generally within the second and third stages of development when an 
instrument was being tested. The exception to this is the CHU9D which was derived using bottom up methods. 
Bottom up methods generally lean themselves better towards patient/public involvement as they typically use 
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focus groups and/or individual interviews when generating items for consideration, testing items and refining an 
instrument [12]. 
 
This top down approach mirrors the common approach historically taken within the general HRQoL instrument 
development literature [12]. This involves generating lists of items drawn from interviews, literature, and expert 
opinion and then a technique such as factor analysis used to develop the dimensions. This approach has been 
followed by the majority of the MAUIs reviewed here. This approach is becoming less common in general 
HRQoL instrument development due to a wider adoption of qualitative techniques and impact following the 
FDA requirement for the development of PRO measures [42] which requires that instruments show evidence 
that items have been generated through taking account of the experience and perspective of the patient group 
[10]. 
 
In the MAUI literature, there has also recently been a move towards more use of qualitative methods, 
particularly when developing new MAUIs and in particular those for condition specific MAUIs [6]. The most 
recently developed generic MAUI, the CHU9D, used qualitative methods and a bottom up approach and 
involved patients/the general paediatric population at all stages of its development. The recent developments of 
the EQ-5D-5L and EQ-5DY have also made use of qualitative methods, in contrast to the development of the 
original EQ-5D-3L which used purely top down methods. The recent development of bolt ons for the EQ-5D 
however, lacked any patient/public involvement. This is one potential area where future research into bolt ons 
like this could easily incorporate the views of patients/the public through qualitative methods. 
 
The advantages of the bottom up approach over a top down approach are that the final instrument is likely to 
have more appropriate language and terminology which should increase the content validity [43]. It is also likely 
there will be an improved responsiveness to change, as it includes outcomes directly from patients that they feel 
are relevant [12]. There are also recent initiatives from health care providers such as the UK NHS, to focus care 
and health service research around meeting patient priorities and inclusion within decision making [44], again, 
encouraging the need for patient/public involvement.   
Involving children (as both patients and the general population) in the development of paediatric measures will 
also increase the likelihood that the measure is valid and reliable for the intended population. The use of 
qualitative methods in the development of the CHU9D allows for easy self-completion of the instrument by the 
child as the language and content was all developed directly from children [39]. The AQoL6D undertook 
semantic testing of the descriptive system with adolescents to ensure that the measure was understood and the 
EQ-5DY development also involved some element of input from children as to the appropriate wording that 
should be used. The AQoL-6D and EQ-5DY were both derived from existing adult measure and the first stage 
of development ± generating items for potential inclusion, did not involve the public/patients. The disadvantage 
of this is that these top down adaptations from adult measures risk missing dimensions pertinent to children and 
also may include dimensions that are irrelevant to children. 
More recent work has seen the development of measures of capability for use in economic evaluation. [45, 46] 
Whilst these measures cannot be used to calculate QALYs, they still provide valuable information in assessing 
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the benefits of interventions. The ICECAP A and ICECAP O are measures of capability for use in adults and 
older people respectively [45, 46]. The descriptive systems of both these measures were developed using 
qualitative methods, involving in depth interviews with relevant populations (adults and older people) to identify 
and refine the attributes that should be included. Subsequent validation of the measures also made extensive use 
of qualitative methods to provide evidence on the validity, again involving interviews with the relevant 
populations. [47,48] The use of qualitative methods here is in contrast to the vast majority of the development of 
generic MAUIs used for calculating QALYs to date. The extensive use of qualitative methods in the 
development of these instruments helps to increase the validity and ensures that patient/user views are 
incorporated in determining what should be included in the descriptive systems and how it should be defined.  
 
It is clear that if we wish to incorporate patient/public views in the development of descriptive systems then the 
use of qualitative methods in the initial stage is ideal. This allows for the greatest input. Later stages could 
follow a more mixed methods approach, such as the use of focus groups to reflect on items for inclusion and 
also quantitative data collected directly from patients which could also be used to select items for inclusion or 
refine a measure. One of the problems in terms of advancing methodology in this area is that previously 
developed instruments are often poorly reported and it is difficult to find literature documenting the 
development of their descriptive systems [12]. As well as traditional focus group and interview techniques, 
future development of descriptive systems could also make use of other qualitative techniques to develop 
attributes, such as meta-ethnography, which was used in the development of the Carer Experience Scale [49].  
 
It seems unlikely that a new generic MAUI for adults will be developed and used extensively, given 
the widespread use and validity of the EQ5D.. It seems more likely that the use of CS MAUIs will increase 
and possibly more bolt ons to existing MAUIs will be developed[27]. Development of descriptive systems in 
these areas would be amenable to taking patient/public views into account through the use of qualitative 
methods and if so, would only serve to increase the validity of MAUIs.   
 
6. Conclusions 
Of all the generic MAUIs reviewed in this paper, the CHU9D has the most patient/public involvement. Children 
were involved at each stage of the development of the instrument and their views about what should be included 
were taken into account. This measure is unique within this set of instruments in that it used a bottom up 
methodology which allows for greater patient/public input. The other MAUIs were developed using top down 
methods, with a mixture of adaptation from existing instruments and/or reviews of the literature/existing 
measures. The most recent development in the adult MAUIs, the development of the EQ-5D-5L has seen a 
much greater level of patient/public involvement and it is likely that the use of qualitative methods and 
patient/public involvement will increase in the future.  
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